SCHEMBL12237263

SCHEMBL12237263

Cc1ccc(S(=O)(=O)CC(=O)c2cccc([N+](=O)[O-])c2)cc1

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.77
PKM P14618 2/20 0.71
ALDH1A1 P00352 5/20 0.65
RECQL P46063 1/20 0.63
HSD11B1 P28845 2/20 0.58
POLB P06746 1/20 0.56
GAA P10253 1/20 0.56
MAPT P10636 2/20 0.56
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
CES2 O00748 1/20 0.51
CES1 P23141 1/20 0.51
LMNA P02545 2/20 0.51
MCOLN3 Q8TDD5 1/20 0.51
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13567563 0.86 HSD11B1 (0.62) KMT2APKMALDH1A1HSD11B1GAA
SCHEMBL28538242 0.81 HSD11B1 (0.72) KMT2APKMRECQLHSD11B1GAA
SCHEMBL4528141 0.81 KMT2A (0.65) KMT2APKMALDH1A1POLBGAA
SCHEMBL30209484 0.80 RECQL (0.68) KMT2APKMALDH1A1RECQLHSD11B1
SCHEMBL28427382 0.80 RECQL (0.68) KMT2APKMALDH1A1RECQLHSD11B1
SCHEMBL2422002 0.78 RECQL (1.00) KMT2APKMALDH1A1RECQLHSD11B1
SCHEMBL28538245 0.77 HSD11B1 (0.91) PKMALDH1A1RECQLHSD11B1POLB
SCHEMBL30209485 0.77 HSD11B1 (0.80) KMT2APKMALDH1A1RECQLHSD11B1
SCHEMBL29609963 0.77 RECQL (0.97) KMT2APKMALDH1A1RECQLHSD11B1
SCHEMBL29012562 0.76 HSD11B1 (0.83) KMT2APKMALDH1A1RECQLHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9387254-B2 Prodrugs and drug-macromolecule conjugates having controlled drug release rates PROLYNX LLC (US) 2016-07-12 US disclosed
US-20140296476-A1 PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES PROLYNX LLC 2014-10-02 US disclosed
US-8680315-B2 Prodrugs and drug-macromolecule conjugates having controlled drug release rates PROLYNX, LLC (US) 2014-03-25 US disclosed
US-20110263502-A1 PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES PROLYNX, LLC 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296476-A1 PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES ABCB1, ABCB11, DNPEP KMT2A 3824/4885PKM 622/4885ALDH1A1 701/4885
US-20110263502-A1 PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES ABCB1, ABCB11, DNPEP KMT2A 3824/4885PKM 622/4885ALDH1A1 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.